Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. (24th September 2018)

• Record Type: Journal Article
• Authors: Casrouge, A; Sauer, A V; Barreira da Silva, R; Tejera-Alhambra, M; Sánchez-Ramón, S; Cancrini, C; Ingersoll, M A; Aiuti, A; Albert, M L
• Is Part Of: Clinical and experimental immunology. Volume 194:Number 2(2018:Nov.)
• Page Start: 166
• Page End: 179
• Publication Date: 2018-09-24
• Subjects: chemokines -- immunodeficiency diseases -- T cells; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.13163
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Dipeptidyl peptidase 4 (DPP4, CD26) is a serine protease that is expressed constitutively by many haematopoietic and non-haematopoietic tissues. It exists as a membrane-associated protein, as well as in an active, soluble form (herein called sDPP4), present at high concentrations in bodily fluids. Despite the proposed use of sDPP4 as a biomarker for multiple diseases, its cellular sources are not well defined. Here, we report that individuals with congenital lymphocyte immunodeficiency had markedly lower serum concentrations of sDPP4, which were restored upon successful treatment and restoration of lymphocyte haematopoiesis. Using irradiated lymphopenic mice and wild-type to Dpp4 –/– reciprocal bone marrow chimeric animals, we found that haematopoietic cells were a major source of circulating sDPP4. Furthermore, activation of human and mouse T lymphocytes resulted in increased sDPP4, providing a mechanistic link between immune system activation and sDPP4 concentration. Finally, we observed that acute viral infection induced a transient increase in sDPP4, which correlated with the expansion of antigen-specific CD8 + T cell responses. Our study demonstrates that sDPP4 concentrations are determined by the frequency and activation state of lymphocyte populations. Insights from these studies will support the use of sDPP4 concentration as a biomarker for inflammatory and infectious diseases. Graphical Abstract: